hydroxychloroquine has been researched along with Asthma in 14 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Asthma: A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To examine the possible usefulness of the immunomodulating antiinflammatory drug, hydroxychloroquine (HCQ), in the treatment of asthma, we studied the response of 11 asthmatics, four severe symptomatic nonsteroid dependent and seven steroid-dependent, in an open label 28 week trial at doses of 300 to 400 mg/d." | 9.06 | Open study of hydroxychloroquine in the treatment of severe symptomatic or corticosteroid-dependent asthma. ( Charous, BL, 1990) |
| "A recent case report suggested that hydroxychloroquine had a steroid sparing effect in a patient with severe chronic asthma." | 9.06 | Hydroxychloroquine in steroid dependent asthma. ( Elliott, JA; Gunneberg, A; Roberts, JA; Thomson, NC, 1988) |
| "The object of this review was to assess the efficacy of adding chloroquine to oral corticosteroids in patients with chronic asthma who are dependent on oral corticosteroids with the intention of minimising or eventually eliminating the use of these oral steroids." | 8.82 | Chloroquine as a steroid sparing agent for asthma. ( Bara, A; Dean, T; Dewey, A; Lasserson, TJ; Walters, EH, 2003) |
| " Four months after returning to work, the patient experienced a first episode of severe asthma and generalized dermatitis with conjunctivitis following exposure to hydroxychloroquine the day before." | 7.70 | [Occupationally-induced contact dermatitis and bronchial asthma in a unusual delayed reaction to hydroxychloroquine]. ( Elsner, P; Meier, H; Wüthrich, B, 1999) |
| "Hydroxychloroquine (HCQ) is a well-tolerated, safe immunomodulating drug, with proven efficacy in rheumatic diseases and known actions that suggest potential utility in the treatment of asthma." | 6.69 | Hydroxychloroquine improves airflow and lowers circulating IgE levels in subjects with moderate symptomatic asthma. ( Charous, BL; Halpern, EF; Steven, GC, 1998) |
| "To examine the possible usefulness of the immunomodulating antiinflammatory drug, hydroxychloroquine (HCQ), in the treatment of asthma, we studied the response of 11 asthmatics, four severe symptomatic nonsteroid dependent and seven steroid-dependent, in an open label 28 week trial at doses of 300 to 400 mg/d." | 5.06 | Open study of hydroxychloroquine in the treatment of severe symptomatic or corticosteroid-dependent asthma. ( Charous, BL, 1990) |
| "A recent case report suggested that hydroxychloroquine had a steroid sparing effect in a patient with severe chronic asthma." | 5.06 | Hydroxychloroquine in steroid dependent asthma. ( Elliott, JA; Gunneberg, A; Roberts, JA; Thomson, NC, 1988) |
| "The object of this review was to assess the efficacy of adding chloroquine to oral corticosteroids in patients with chronic asthma who are dependent on oral corticosteroids with the intention of minimising or eventually eliminating the use of these oral steroids." | 4.82 | Chloroquine as a steroid sparing agent for asthma. ( Bara, A; Dean, T; Dewey, A; Lasserson, TJ; Walters, EH, 2003) |
| " Four months after returning to work, the patient experienced a first episode of severe asthma and generalized dermatitis with conjunctivitis following exposure to hydroxychloroquine the day before." | 3.70 | [Occupationally-induced contact dermatitis and bronchial asthma in a unusual delayed reaction to hydroxychloroquine]. ( Elsner, P; Meier, H; Wüthrich, B, 1999) |
| "Hydroxychloroquine (HCQ) is a well-tolerated, safe immunomodulating drug, with proven efficacy in rheumatic diseases and known actions that suggest potential utility in the treatment of asthma." | 2.69 | Hydroxychloroquine improves airflow and lowers circulating IgE levels in subjects with moderate symptomatic asthma. ( Charous, BL; Halpern, EF; Steven, GC, 1998) |
| " Further, almost all of the trials registered do not consider dosage adjustment in the elderly, a patient population most likely to require HCQ treatment." | 1.56 | Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19. ( Arthur, A; Dayton, F; Farragher, JP; Kavanagh, O; Mahoney, B; Marie Healy, A; O'Reilly, NJ; Robinson, S; Walker, G, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (21.43) | 18.7374 |
| 1990's | 8 (57.14) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| García-Moguel, I | 1 |
| Díaz Campos, R | 1 |
| Alonso Charterina, S | 1 |
| Fernández Rodríguez, C | 1 |
| Fernández Crespo, J | 1 |
| Kavanagh, O | 1 |
| Marie Healy, A | 1 |
| Dayton, F | 1 |
| Robinson, S | 1 |
| O'Reilly, NJ | 1 |
| Mahoney, B | 1 |
| Arthur, A | 1 |
| Walker, G | 1 |
| Farragher, JP | 1 |
| MORIYA, K | 1 |
| MATSUURA, Y | 1 |
| KIMURA, I | 1 |
| TIODA, J | 1 |
| Dean, T | 1 |
| Dewey, A | 1 |
| Bara, A | 1 |
| Lasserson, TJ | 1 |
| Walters, EH | 1 |
| Goldstein, JA | 1 |
| Hill, JM | 1 |
| Tattersfield, AE | 1 |
| Moss, RB | 1 |
| Spector, SL | 1 |
| Charous, BL | 3 |
| Halpern, EF | 1 |
| Steven, GC | 1 |
| Meier, H | 1 |
| Elsner, P | 1 |
| Wüthrich, B | 1 |
| Szefler, SJ | 1 |
| Roberts, JA | 1 |
| Gunneberg, A | 1 |
| Elliott, JA | 1 |
| Thomson, NC | 1 |
5 reviews available for hydroxychloroquine and Asthma
| Article | Year |
|---|---|
Chloroquine as a steroid sparing agent for asthma.
Topics: Adrenal Cortex Hormones; Asthma; Chloroquine; Humans; Hydroxychloroquine; Randomized Controlled Tria | 2003 |
Corticosteroid sparing agents in asthma.
Topics: Adrenal Cortex Hormones; Asthma; Cyclosporine; Gold; Humans; Hydroxychloroquine; Methotrexate | 1995 |
Alternative pharmacotherapies for steroid-dependent asthma.
Topics: Adrenal Cortex Hormones; Asthma; Clinical Trials as Topic; Cyclosporine; Dapsone; Furosemide; Gold; | 1995 |
Alternative treatments in the patient with intractable asthma.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Infective Agents; Antirheumatic Agents; Asthma; | 1997 |
Anti-inflammatory drugs in the treatment of allergic disease.
Topics: Adrenergic beta-Agonists; Anti-Inflammatory Agents; Asthma; Auranofin; Bronchodilator Agents; Cromol | 1992 |
3 trials available for hydroxychloroquine and Asthma
| Article | Year |
|---|---|
Hydroxychloroquine improves airflow and lowers circulating IgE levels in subjects with moderate symptomatic asthma.
Topics: Adolescent; Adult; Aged; Anti-Asthmatic Agents; Asthma; Double-Blind Method; Female; Follow-Up Studi | 1998 |
Open study of hydroxychloroquine in the treatment of severe symptomatic or corticosteroid-dependent asthma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Asthma; Clinical Trials as Topic; Forced Expiratory Volume; Hu | 1990 |
Hydroxychloroquine in steroid dependent asthma.
Topics: Adult; Asthma; Beclomethasone; Double-Blind Method; Female; Humans; Hydroxychloroquine; Male; Middle | 1988 |
6 other studies available for hydroxychloroquine and Asthma
| Article | Year |
|---|---|
COVID-19, severe asthma, and biologics.
Topics: Acetates; Adrenergic beta-2 Receptor Antagonists; Amoxicillin-Potassium Clavulanate Combination; Ant | 2020 |
Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Asthma; Betacoronavirus; Clinical Trials, Phase | 2020 |
[Studies on bronchial asthma therapy using quinoline derivatives. On results of orotic acid-chloroquine therapy].
Topics: Anti-Infective Agents, Local; Asthma; Chloroquine; Dermatologic Agents; Hydroxychloroquine; Hydroxyq | 1961 |
Hydroxychloroquine for asthma.
Topics: Adult; Asthma; Humans; Hydroxychloroquine; Male | 1983 |
[Occupationally-induced contact dermatitis and bronchial asthma in a unusual delayed reaction to hydroxychloroquine].
Topics: Asthma; Bronchial Provocation Tests; Dermatitis, Contact; Drug Industry; Forced Expiratory Volume; H | 1999 |
Effectiveness of long-term treatment of severe asthma with hydroxychloroquine (HCQ).
Topics: Asthma; Follow-Up Studies; Forced Expiratory Flow Rates; Humans; Hydroxychloroquine; Inflammation | 1991 |